Stocks › ARWR

ARROWHEAD PHARMACEUTICALS, INC.

ARWR·Nasdaq·United States United States·USD
$41.37
-2.28 (-5.22%)
Close · Nov 20, 2026 · Close Prices from Tiingo.com
ARWR
ARROWHEAD PHARMACEUTICALS, INC. · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
ARWRS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair

Congressional Trades

Recent trades of ARWR by members of U.S. Congress · 1 on record
All congressional trades →
PoliticianStockTypeFiledTraded
Daniel S. GoldmanDaniel S. GoldmanHouse · D · NY ARWRARROWHEAD PHARMACEUTICALS, INC. · Stock Sale
$1,001 - $15,000
Feb 24, 2023 Jan 31, 2023 Filing ↗

Whale Activity

Position changes in ARWR reported for 2026-09-30 by 559 institutional filers
Increased: 172New: 64Held: 62Decreased: 166Closed: 72No prior filing: 23
  • Increased172
  • New64
  • Held62
  • Decreased166
  • Closed72
  • No prior filing23
FilerSharesValueChange
BlackRock, Inc.15.1M$991.0Mincreased
Avoro Capital Advisors LLC11.0M$720.0Mdecreased
FMR LLC9.4M$612.3Mincreased
VANGUARD PORTFOLIO MANAGEMENT LLC6.2M$406.5Mdecreased
STATE STREET CORP6.1M$400.7Mincreased
VANGUARD CAPITAL MANAGEMENT LLC6.1M$400.5Mincreased
Vestal Point Capital, LP4.8M$315.1Mincreased
Invesco Ltd.3.8M$250.4Mdecreased
GEODE CAPITAL MANAGEMENT, LLC3.5M$234.5Mdecreased
FRED ALGER MANAGEMENT, LLC3.3M$213.1Mdecreased
Siren, L.L.C.2.3M$149.9Mincreased
MORGAN STANLEY1.8M$120.1Mincreased

Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.

Insider Trading

Net shares bought (+) or sold (−) on the open market by ARWR insiders, by quarter · Form 4
-500.0K-250.0K0250.0K500.0K2025 Q1: -479.0K2025 Q12025 Q2: -141.1K2025 Q22025 Q3: -40.0K2025 Q32025 Q4: -428.0K2025 Q42026 Q1: -112.8K2026 Q12026 Q2: -26.1K2026 Q22026 Q3: -13.6K2026 Q32026 Q4: 02026 Q4

Recent Insider Transactions

744 transactions on record · newest first
All insider activity →
InsiderTypeSharesPriceValueDate
PERRY MICHAEL SDirector Sale −11.6K $87.30 $1.0M Aug 18, 2026 Form 4 ↗
OLUKOTUN ADEOYE YDirector Sale −2,000 $86.96 $174K Aug 18, 2026 Form 4 ↗
Cohen Matthew GregoryDirector Grant / award +11.9K $0.00 $0 Jun 15, 2026 Form 4 ↗
Lu HongboDirector Sale −2,970 $76.88 $228K May 12, 2026 Form 4 ↗
Hamilton James CChief Medical Officer Sale −10.0K $75.00 $750K Apr 23, 2026 Form 4 ↗
Apel Daniel JosephChief Financial Officer Sale −8,730 $71.92 $628K Apr 22, 2026 Form 4 ↗
Apel Daniel JosephChief Financial Officer Sale −1,157 $70.45 $82K Apr 22, 2026 Form 4 ↗
Apel Daniel JosephChief Financial Officer Sale −3,208 $70.11 $225K Apr 22, 2026 Form 4 ↗
Hamilton James CChief Medical Officer Sale −10.0K $64.19 $642K Mar 5, 2026 Form 4 ↗
Apel Daniel JosephChief Financial Officer Grant / award +75.0K $0.00 $0 Jan 6, 2026 Form 4 ↗
Hamilton James CChief Medical Officer Grant / award +75.0K $0.00 $0 Jan 6, 2026 Form 4 ↗
O'Brien PatrickCOO Grant / award +75.0K $0.00 $0 Jan 6, 2026 Form 4 ↗
O'Brien PatrickCOO Gift −440 $0.00 $0 Jan 6, 2026 Form 4 ↗
O'Brien PatrickCOO Gift −440 $0.00 $0 Jan 6, 2026 Form 4 ↗
O'Brien PatrickCOO Gift −540 $0.00 $0 Jan 6, 2026 Form 4 ↗
O'Brien PatrickCOO Gift −540 $0.00 $0 Jan 6, 2026 Form 4 ↗
O'Brien PatrickCOO Gift −540 $0.00 $0 Jan 6, 2026 Form 4 ↗
Hamilton James CChief Medical Officer Sale −309 $68.00 $21K Jan 5, 2026 Form 4 ↗
Hamilton James CChief Medical Officer Sale −437 $65.97 $29K Jan 5, 2026 Form 4 ↗
Hamilton James CChief Medical Officer Sale −1,200 $64.49 $77K Jan 5, 2026 Form 4 ↗

Fund Holders

Mutual funds and ETFs holding ARWR · SEC Form N-PORT
FundSharesValue% of fundAs of
iShares Core S&P Mid-Cap ETF
iShares Trust
4.8M$392.9M0.32%Jun 30, 2026
VANGUARD TOTAL STOCK MARKET INDEX FUND
VANGUARD INDEX FUNDS
4.2M$346.1M0.02%Jun 30, 2026
VANGUARD SMALL-CAP INDEX FUND
VANGUARD INDEX FUNDS
3.1M$250.1M0.13%Jun 30, 2026
Fidelity Growth Company Fund
Fidelity Mt. Vernon Street Trust
2.6M$214.5M0.22%Aug 31, 2026
Invesco S&P MidCap Momentum ETF
Invesco Exchange-Traded Fund Trust
1.7M$147.0M2.05%Jul 31, 2026
VANGUARD SMALL-CAP GROWTH INDEX FUND
VANGUARD INDEX FUNDS
1.8M$144.2M0.31%Jun 30, 2026
VANGUARD EXTENDED MARKET INDEX FUND
VANGUARD INDEX FUNDS
1.6M$131.6M0.13%Jun 30, 2026
State Street(R) SPDR(R) S&P(R) Biotech ETF
SPDR SERIES TRUST
1.4M$114.7M1.07%Jun 30, 2026
Fidelity Small Cap Index Fund
Fidelity Salem Street Trust
1.3M$98.3M0.30%Apr 30, 2026
First Trust NYSE Arca Biotechnology Index Fund
First Trust Exchange-Traded Fund
1.2M$95.0M3.38%Jun 30, 2026

Mutual funds and ETFs whose N-PORT filings list ARWR's shares (CUSIP 04280A100), each fund at its latest report since Apr 21, 2026, largest positions first. Bonds, options and short positions are left out.

Activist & Passive Stakes

Schedule 13D / 13G beneficial-ownership filings
  • Abigail P. JohnsonSCHEDULE 13G/A · passive (13G) · 9.3M shares6.6%
    Nov 5, 2026 · ↗
  • FMR LLCSCHEDULE 13G/A · passive (13G) · 9.3M shares6.6%
    Nov 5, 2026 · ↗
  • Behzad AghazadehSCHEDULE 13G/A · passive (13G) · 13.8M shares9.6%
    Aug 14, 2026 · ↗
  • Avoro Capital Advisors LLCSCHEDULE 13G/A · passive (13G) · 13.8M shares9.6%
    Aug 14, 2026 · ↗
  • Vanguard Portfolio ManagementSCHEDULE 13G/A · passive (13G) · 6.4M shares4.5%
    Jul 31, 2026 · ↗
  • BlackRock, Inc.SCHEDULE 13G/A · passive (13G) · 14.2M shares10.1%
    Jul 27, 2026 · ↗
  • Abigail P. JohnsonSCHEDULE 13G · passive (13G) · 7.3M shares5.2%
    May 6, 2026 · ↗
  • FMR LLCSCHEDULE 13G · passive (13G) · 7.3M shares5.2%
    May 6, 2026 · ↗

Corporate Lobbying

Estimated quarterly lobbying spending reported under the LDA, filings naming ARROWHEAD PHARMACEUTICALS, INC. as client

No lobbying filings found naming ARROWHEAD PHARMACEUTICALS, INC. as the client.

Government Contracts

Federal awards to ARROWHEAD PHARMACEUTICALS, INC. · USAspending

No federal contract awards found for ARROWHEAD PHARMACEUTICALS, INC..

U.S. Patents

Recent USPTO applications naming ARROWHEAD PHARMACEUTICALS, INC.

No USPTO patent applications found for ARROWHEAD PHARMACEUTICALS, INC..

Annual Financials

From ARWR's 10-K filings · XBRL
Fiscal yearFY2026FY2025FY2024FY2023FY2022
Revenue$450.8M$829.4M$3.6M$240.7M$243.2M
Operating income-$707.2M$98.3M-$601.1M-$205.0M-$178.5M
Net income-$724.2M-$1.6M-$599.5M-$205.3M-$176.1M
Diluted EPS-$5.11-$0.01-$5.00-$1.92-$1.67
Operating cash flow-$271.9M$179.6M-$462.9M-$153.9M-$136.1M
Total assets$1.74B$1.39B$1.14B$765.6M$691.9M
Shareholders' equity$50.3M$466.1M$185.4M$271.3M$398.5M

As ARROWHEAD PHARMACEUTICALS, INC. tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Nov 12, 2026 ↗

Stock Splits

Every split and reverse split in the price history
  • 1-for-10Reverse splitNov 17, 2011
  • 1-for-65Reverse splitJan 15, 2004

Split dates and ratios from the price history · Close Prices from Tiingo.com

Material Events (8-K)

Corporate events filed with the SEC
  • 8-K · Items 2.02, 9.01Results of operationsNov 12, 2026
    EDGAR ↗
  • 8-K · Items 1.01, 2.03Material agreement · Direct financial obligationNov 4, 2026
    EDGAR ↗
  • 8-K · Items 2.02, 9.01Results of operationsAug 4, 2026
    EDGAR ↗
  • 8-K · Items 5.02, 9.01Officer / director changeJun 16, 2026
    EDGAR ↗
  • 8-K · Items 2.02, 9.01Results of operationsMay 7, 2026
    EDGAR ↗

About ARROWHEAD PHARMACEUTICALS, INC.

From SEC EDGAR company records

A.Overview The Company develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and modes of delivery, the Company’s therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. There are approximately 20 Arrowhead discovered drug candidates in clinical trials ranging from early stage (Phase 1) to late stage (Phase 3), including both partnered and wholly-owned candidates. In addition, the Company has a robust discovery stage pipeline which is capable of generating multiple new clinical candidates each year. The Company achieved a transformational milestone with its fi…

Industry (SIC 2834)Pharmaceutical Preparations
SectorHealthcare
HeadquartersPASADENA, CA
IncorporatedDE
Former namesARROWHEAD RESEARCH CORP, INTERACTIVE GROUP INC, INTERACTIVE INC